Form 4: BridgeBio CFO Sells Shares Under 10b5-1 Plan

BridgeBio Pharma's President and CFO, Thomas Trimarchi, sold a portion of his common stock holdings, including shares withheld for tax obligations and sales under a pre-arranged 10b5-1 plan.

Summary

• Thomas Trimarchi, President and CFO of BridgeBio Pharma, Inc. (BBIO), reported transactions involving the company's common stock.
• On August 16, 2025, 21,317 shares of common stock were withheld to satisfy tax obligations in connection with the vesting of 38,547 Restricted Stock Units (RSUs).
• On August 18, 2025, Trimarchi sold 15,380 shares of common stock at a weighted average price of $50.1437 per share, with prices ranging from $49.76 to $50.75.
• On the same day, August 18, 2025, an additional 1,973 shares of common stock were sold at a weighted average price of $50.9439 per share, with prices ranging from $50.83 to $50.95.
• Both sales on August 18, 2025, were executed pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
• Following these reported transactions, Thomas Trimarchi beneficially owns 463,318 shares of BridgeBio Pharma common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions appear routine, involving tax withholding and pre-planned sales under a 10b5-1 plan, which mitigates concerns about opportunistic selling based on non-public information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned disposition rather than a reaction to new, negative information.
• A significant portion of the disposition was due to tax withholding on RSU vesting, which is a common and routine event for executive compensation.

Negatives

• Insider selling, even if pre-planned, reduces the insider's direct equity stake in the company.
• The sales occurred at prices between $49.76 and $50.95, which might be seen as management taking profits.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider stock transactions and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The reduction in the CFO's direct ownership stake, though minor and pre-planned, could be noted by investors.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details routine insider stock transactions, including sales under a pre-arranged 10b5-1 plan and shares withheld for tax obligations. These are not indicative of new fundamental information about the company's performance or outlook. Therefore, the filing itself does not provide a basis for a change in investment recommendation; a 'hold' stance is appropriate, pending further fundamental analysis of the company's operations and financial results.

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Trading, Thomas Trimarchi, Stock Sale, Rule 10b5-1, Restricted Stock Units, CFO